Published on 22/12/2025
The AllTrials Campaign: Achievements, Advocacy, and Ongoing Gaps
Origins of the AllTrials Movement
The AllTrials campaign was launched in January 2013 by a coalition of advocacy groups and scientific leaders including Sense About Science, the BMJ, the Cochrane Collaboration, and Ben Goldacre. Its core message was simple yet bold: “All trials registered. All results reported.” This call to action was directed toward pharmaceutical companies, regulatory authorities, universities, and journals that were collectively responsible for a long-standing issue in biomedical research—non-disclosure of trial results.
Before the campaign, many clinical trials, especially those with negative or neutral outcomes, remained unpublished. This publication bias skewed the evidence base used by doctors, patients, and policymakers. AllTrials aimed to fix that by demanding mandatory trial registration and public result reporting for all clinical studies—past, present, and future.
Core Objectives and Methods of Advocacy
At its core, AllTrials sought to rectify a major ethical and scientific problem: the suppression of clinical trial data. Its objectives included:
- Universal registration of all trials before the first subject is enrolled
- Public availability of trial protocols and results in a timely fashion
- Inclusion of legacy trials in disclosure mandates
- Development of policy frameworks that would legally enforce transparency
The campaign used
Impact on Global Clinical Trial Reporting Standards
One of the most profound successes of the campaign was its influence on global transparency legislation and sponsor practices. While correlation does not imply causation, the following events followed the surge in AllTrials advocacy:
- The EMA introduced Policy 0070 to make clinical data publicly available
- The EU Clinical Trial Regulation 536/2014 mandated result posting on EudraCT
- The FDA Amendments Act (FDAAA) Final Rule in the U.S. began enforcement in 2017
- ClinicalTrials.gov and WHO ICTRP saw significant upticks in trial postings
Furthermore, major pharmaceutical sponsors like GSK, Johnson & Johnson, and Roche initiated voluntary public trial result portals, inspired in part by public and regulatory pressure amplified by AllTrials.
Academic Shifts and Journal Policy Alignment
Academic journals responded to the movement by tightening their requirements. The ICMJE reaffirmed its stance on mandatory trial registration, and leading journals such as The BMJ, PLOS Medicine, and The Lancet supported retrospective disclosures of missing results. Universities began requiring investigators to post results as a condition of grant renewals or tenure promotion.
Transparency Tools and Monitoring Mechanisms
To maintain momentum, developers and researchers launched digital tracking tools that publicly shamed non-compliant sponsors and institutions. Tools like the FDAAA Trials Tracker from the University of Oxford provided real-time data on trial result submission rates. These platforms monitored sponsors’ performance and highlighted areas where compliance was lagging.
Such initiatives brought greater public scrutiny and media coverage to institutions failing to meet basic transparency expectations. Reports and dashboards ranked companies by compliance percentages and deadlines, creating incentives for reform.
Challenges and Criticisms Faced by the AllTrials Campaign
Despite success, AllTrials faced several roadblocks:
- Retrospective Reporting: Many older trials remain undisclosed, and no universal mechanism exists to mandate their publication.
- Variable Global Policies: Discrepancies across registries such as ClinicalTrials.gov, EudraCT, and Japan’s JPRN hinder unified compliance.
- Enforcement Limitations: Few sponsors face actual penalties for non-compliance.
- Academic Gaps: Investigator-led trials often fall through the cracks due to lack of oversight or awareness.
Moreover, despite support from large sponsors, the campaign struggled to gain momentum in lower- and middle-income countries due to resource constraints and weak infrastructure.
Ethical Relevance and Regulatory Oversight
The ethical implications of undisclosed trials are substantial. Patients who participate in research do so with the belief that their contribution will benefit future healthcare decisions. Non-disclosure betrays this trust and leads to wasteful duplication of research. Regulatory authorities like the FDA, EMA, and WHO have all issued guidelines emphasizing the importance of timely trial reporting, yet implementation varies by region.
According to a WHO joint statement, all trials should be registered and their results reported within 12 months of study completion—a goal still unmet globally. WHO’s position paper on disclosure practices has reinforced AllTrials’ advocacy at a policy level. (See WHO Publications).
Legacy and the Way Forward
The AllTrials campaign catalyzed a new era of clinical research ethics and data sharing. While gaps persist, it elevated transparency to a global priority and reshaped stakeholder behavior. Today, regulatory teams and sponsors rely on established SOPs, validation templates, and audit tools to stay compliant. Platforms like PharmaSOP.in offer implementation guides that institutionalize disclosure workflows.
Going forward, greater automation, registry harmonization, and public accountability will be key. Institutional Review Boards (IRBs), funders, and journals must continue to pressure lagging institutions until transparency becomes standard operating procedure worldwide.
Conclusion
The AllTrials campaign marked a turning point in clinical trial history. It transformed hidden results into a public debate, empowered patients and researchers alike, and improved ethical norms across the pharmaceutical industry. Yet, full transparency is still a work in progress. Continued collaboration between regulatory bodies, sponsors, ethics committees, and advocacy groups will be essential to realize the vision of complete, accessible, and trustworthy clinical trial data for all.